Literature DB >> 22898137

Overexpression of BMI-1 is associated with poor prognosis in cervical cancer.

Yong-Qing Tong1, Bei Liu, Hong-Yun Zheng, Yu-Juan He, Jian Gu, Feng Li, Yan Li.   

Abstract

AIM: It has been reported that BMI-1, a gene transcription promoter overexpressed in various human cancers, is associated with poor survival. We investigated whether BMI-1 is a marker for cervical cancer by detecting the expression of BMI-1 in cervical cancer.
METHODS: An immunohistochemistry (IHC) streptavidin-peroxidase technique was used to identify BMI-1 protein expression in 302 cervical cancer specimens. Reverse transcription polymerase chain reaction and Western blot were employed to measure BMI-1 mRNA and protein level. The correlation between BMI-1 expression and clinicopathological factors was analyzed.
RESULTS: Both BMI-1 mRNA and protein expression were evident in cervical carcinoma tissues. An intense positive rate of 55.3% (167/302) was observed by IHC. High BMI-1 expression was correlated with clinical stage, lymph node metastasis, vascular invasion and human papillomavirus (HPV) infection (P < 0.05), but there is insufficient evidence to confirm its value in tumor size, age, estrogen or progesterone receptor (P > 0.05). The BMI-1 protein level was positively correlated with the clinical stages of cervical carcinoma and a high BMI-1 expression was associated with poor prognosis (P < 0.05).
CONCLUSION: The high expression of BMI-1 in cervical cancer is related to tumor progression, lymph node metastasis and HPV infection, suggesting that cervical cancer with excessive BMI-1 expression possesses high metastases potential and that BMI-1 may be a promising biomarker for predicting metastasis in cervical cancer.
© 2012 Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22898137     DOI: 10.1111/j.1743-7563.2012.01564.x

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  14 in total

1.  Silencing Bmi-1 enhances the senescence and decreases the metastasis of human gastric cancer cells.

Authors:  Feng-Lan Gao; Wei-Shan Li; Chun-Ling Liu; Guo-Qiang Zhao
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

Review 2.  Embryonic stem cell-specific signature in cervical cancer.

Authors:  Jorge Organista-Nava; Yazmín Gómez-Gómez; Patricio Gariglio
Journal:  Tumour Biol       Date:  2013-10-28

Review 3.  Cervical cancer stem cells: opportunities and challenges.

Authors:  Ravindresh Chhabra
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-07       Impact factor: 4.553

Review 4.  Potential role of cancer stem cells as biomarkers and therapeutic targets in cervical cancer.

Authors:  Niyati Sudhalkar; Nidul P Rathod; Ashwathi Mathews; Supriya Chopra; Harshini Sriram; Shyam K Shrivastava; Jayant S Goda
Journal:  Cancer Rep (Hoboken)       Date:  2018-11-08

5.  miR-376c inhibits cervical cancer cell proliferation and invasion by targeting BMI1.

Authors:  Youping Deng; Yan Xiong; Yingjuan Liu
Journal:  Int J Exp Pathol       Date:  2016-06-27       Impact factor: 1.925

Review 6.  BMI1: A Biomarker of Hematologic Malignancies.

Authors:  Anagh A Sahasrabuddhe
Journal:  Biomark Cancer       Date:  2016-05-05

7.  Expression of B cell-specific Moloney murine leukemia virus integration site 1 in vulvar squamous cell carcinoma and its effect on the biological behavior of A-431 cells.

Authors:  Xueli Bai; Ling Ouyang; B O Li; Yang Zhou; Xin Wen
Journal:  Oncol Lett       Date:  2015-09-25       Impact factor: 2.967

8.  Upregulation of the proto-oncogene Bmi-1 predicts a poor prognosis in pediatric acute lymphoblastic leukemia.

Authors:  Hong-Xia Peng; Xiao-Dan Liu; Zi-Yan Luo; Xiao-Hong Zhang; Xue-Qun Luo; Xiao Chen; Hua Jiang; Ling Xu
Journal:  BMC Cancer       Date:  2017-01-25       Impact factor: 4.430

9.  B3GNT3 Expression Is a Novel Marker Correlated with Pelvic Lymph Node Metastasis and Poor Clinical Outcome in Early-Stage Cervical Cancer.

Authors:  Weijing Zhang; Teng Hou; Chunhao Niu; Libing Song; Yanna Zhang
Journal:  PLoS One       Date:  2015-12-28       Impact factor: 3.240

10.  Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.

Authors:  Arnold Bolomsky; Karin Schlangen; Wolfgang Schreiner; Niklas Zojer; Heinz Ludwig
Journal:  J Hematol Oncol       Date:  2016-03-02       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.